| Chief Investigator:
|| Professor Gary Middleton
|| University of Birmingham
|| Merk, Sharp and Dohme
| Disease Site:
|| Non-Small Cell Lung Cancer with a Performace Status of 2
| Trial Type:
|| Clinical Trial of an Investigational Medicinal Product
|| Follow Up
| UKCRN Study ID (if applicable):
| Open to New Sites?
| Recruitment End Date:
|| February 2018
| CRCTU Trial Management Team:
|| Early Drug Development Team
| Trial Email Address:
Many patients with lung cancer have impaired performance status (PS), a measure of a patient’s general well-being and daily activity. This means that they are ineligible for trials of new therapies including pembrolizumab (anti PD-1): all of the trials of this drug reported thus far have been in patients with PS 0-1.
The favourable safety profile of pembrolizumab suggests that it may represent an excellent choice for PS2 patients.
In this trial, PS2 patients with non-small cell lung cancer will be treated with the anti-PD1 antibody, to assess toxicity, safety, response rate and duration of response.
Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible.
Clinical trial protocols are complex technical documents which should only be used for the treatment of subjects taking part in the trial. Patients who are interested in taking part in the trial are advised to talk to their health care professional refer to CancerHelp website see the link below.
Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference.